ARV regimen started during the first 29 days of life can be continued however the DHHS panel recommends considering switching to a DTG containing regimen as outlined below DTG is preferred due to greater efficacy and durability vs RAL and NVP ease of DTG

ARV regimen started during the first 29 days of life can be continued; however, the DHHS panel recommends considering switching to a DTG-containing regimen, as outlined below. DTG is preferred due to greater efficacy and durability vs. RAL and NVP, ease of DTG dispersible tablet preparation, and availability in FDC form. NRTI backbone may be continued w/ DTG, no change required.